Avid Bioservices Inc (CDMO)

[biopharm]

Exciting times ahead for Avid IP assets, though the Avid Bioservices have made a clear attempt to cut off shareholders and their requests to make it onto the homepage and further, let shareholders know what protection they have in place re: Oncologie Inc restricting access to PS Targeting collaborations

I doubt some IIS knew how close RTW and Perceptive and others are to Merck

How many trials are active right now ..publically .. with PS Targeting?

How many are not known to Avid shareholders ...and worse, Avid BOD playing dumb

_____

Brekken Lab(before it was merged with Dr. Thorpes Lab)

Juliet Carbon
Jason Toombs
Shanna Arnold
Lee Rivera
Marie Burdine
Laura Sullivan
Kristi Lynn
Amanda Kirane
Mike Dellinger
Puja Gupta
Christina Roland
Sean Dineen

Collaborators:
Jason Fleming – MDACC
Thomas Wilkie
John Minna
Joan Schiller
Philip Thorpe
Roderich Schwarz
Adi Gazdar
Hiromi Yanagisawa
Tom Kodadek- Scripps
Joyant Pharmaceuticals

https://www.pancan.org/section_facing_pancreatic_cancer/learn_about_pan_cancer/educational_events/past_symposia_presentions/dallas10/Research%20in%20Pancreatic%20Cancer_Brekken.pdf

_____

Immunovant is merging with Health Sciences Acquisitions Corporation, a $115 million blank check company sponsored by RTW Investments and backed by Adage Capital, Cormorant, Eventide and Perceptive Advisors. In addition to around $100 million confirmed to be in the bank, RTW and Roivant, alongside BVF Partners, have put together a $35 million private “bridge financing.”

“We believe IMVT-1401 is a uniquely compelling asset within the FcRn drug class, which we expect will become a cornerstone therapy for treating many auto-antibody driven diseases,” said Roderick Wong, the chief investment officer of RTW, who took charge of HSAC, in a statement.

Wong will now step aside from the helm to make room for Immunovant CEO Pete Salzmann to run the combined entity, of which current Immunovant shareholders will retain 77%. They may be awarded more shares if the price goes up.

The neonatal Fc receptor (FcRn) target is believed to be implicated in a range of IgG-mediated autoimmune diseases. Immunovant was founded last year after licensing its lead compound — a subcutaneous injection — from South Korea’s HanAll Biopharma.

Salzmann, an Eli Lilly vet, has steered the drug through a Phase I program and kicked off Phase IIa trials for Graves’ ophthalmopathy and myasthenia gravis, both of which will be funded by the transaction. A third IND is planned for warm autoimmune hemolytic anemia.

Immunovant is the fourth public company among Roivant’s subsidiaries, a group that has grown to 20 — though only 16 have been disclosed, with the latest introduction of Cytovant. Ramaswamy, who’s built his Vant empire on a web of deals, has managed to secure sizable IPOs for Axovant, Myovant and Urovant, though all their shares have slide substantially since respective public debuts.

Execs had originally pencilled in a $100 million IPO for Dermavant, but after postponing that plan once they officially withdrew the application on the same day Roivant announced a sweeping $3 billion deal with Sumitomo Dainippon Pharma that gives the Japanese pharma rights to at most 11 Vants (Dermavant was not explicitly named).


https://endpts.com/vivek-ramaswamy-engineers-new-deal-with-rtw-to-take-pete-salzmanns-immunovant-public/